- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02496975
Traumatic Brain Injury and Effects of Acute Cyclosporine A
Oxidative Damage and Calcium-Activated Proteolytic Biomarkers After Traumatic Brain Injury and Effects of Acute Cyclosporine A
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this research study is to measure the chemicals produced by the brain after it is injured and also if Cyclosporine A treatment changes these chemicals. By doing this study, the investigators hope to learn if cyclosporine A therapy helps patients with this injury.
The research procedures will happen at the University of Kentucky (UK) Chandler Medical Center. The study will last for the first 7 days while the participant is admitted to UK Medical Center, or until they are released. Participants will not be asked to stay longer in the hospital for this research study.
Participants in this study will receive all therapies currently available for treatment of severe brain injury. Each participant will be assigned randomly (by chance) to either placebo (a substance without active drug) or cyclosporine A treatment. Neither the participant nor any of the study personnel will know what study treatment has been assigned to the participant.
If assigned to the cyclosporine A treatment group (study drug) participants will be continuously administered the study drug through a tube placed into the vein. A placebo will be given to participants assigned to the placebo group.
Blood and cerebrospinal fluid will be collected at the following time points (12, 24, 36, 48, 60 and 72 hours) for research purposes. These tests will help us understand the participant's ability to make red and white blood cells to fight infection, how well their kidneys function, how well their liver functions, and triglyceride/cholesterol levels.
Cerebrospinal fluid will only be collected from participants who have a drain catheter placed as part of their routine care.
Daily blood collections will occur so the investigators can measure how much of the study drug is present, to assess the body chemicals from the brain and also for safety. Blood samples will be collected by using an already placed line through a vein or artery, or by puncturing the skin with a needle. The chemicals will be measured daily in the urine and also any fluid draining from the line placed into the head for medical management for up to 7 days.
Any unexpected events (side effects) possibly caused by cyclosporine A will be noted and medically managed by the physician. The investigators will be notified when there is need for intervention.
After up to three days of continuous dosing, the study drug will be stopped, but the participant will continue to be carefully monitored for up to 7 days, or until they are released.
Participants will receive the usual treatment for severe traumatic brain injury in addition to receiving the cyclosporine A treatment or placebo.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is between the ages of 18 and 65
- Participant speaks and understands English
- CT Scan evidence of severe TBI
- Post resuscitation GSC 4-8 with at least one reactive pupil
- motor score of greater than 5
- Study medication will be administered within 8 hours injury
Exclusion Criteria:
- Participant received high dose systemic corticosteroids, such as Methylprednisolone >15 mg/kg or equivalent,
- Participant has a known allergy to cyclosporine A,
- Participant is pregnant,
- Participant is less than 18 years of age or greater than 65 years of
- Participant has a history of kidney problems, history of stroke or spinal cord injury,
- Participant has a history of cardiovascular disease, or use of immunosuppressive therapy in the last three months,
- Participant has a history of malignant tumors unless they have been in remission at least five years.
- Participant has an active infection
- Participant has taken part in another investigational trial within the last 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cyclosporine A
Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
|
Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
|
Active Comparator: Placebo
Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
|
Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum lipid peroxidation products: isoprostanes and neuroprostaneses measured by gas-chromatography with mass spectometry
Time Frame: first 7 days after TBI
|
Serum lipid peroxidation products will be measured by gas-chromatography with mass spectometry
|
first 7 days after TBI
|
Cerebrospinal fluid (CSF) calpain-mediated cytoskeletal breakdown products measured by western blotting
Time Frame: first 7 days after TBI
|
cytoskeletal breakdown products will be measured by western blotting
|
first 7 days after TBI
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ICP Therapy Intensity Level (TIL) Summary
Time Frame: first 7 days after TBI
|
The intensity of the use of therapeutic maneuvers to maintain intracranial pressure levels below 20 mm Hg
|
first 7 days after TBI
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Edward Hall, PhD, Sponsor-Investigator
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries
- Wounds and Injuries
- Brain Injuries, Traumatic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- 14-0469-F6A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
-
First Affiliated Hospital Xi'an Jiaotong UniversityXijing Hospital; Second Affiliated Hospital of Wenzhou Medical University; Central... and other collaboratorsRecruitingMTBI - Mild Traumatic Brain Injury | Moderate Traumatic Brain InjuryChina
Clinical Trials on Cyclosporine A
-
AllerganCompletedDry Eye SyndromesUnited States
-
Zambon SpAEnrolling by invitationBronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative BronchiolitisFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
-
Bing HanCompletedPure Red Cell Aplasia, AcquiredChina
-
University Hospital, RouenCompletedKidney Transplantation | Primary Prevention | Kidney Failure
-
LEO PharmaWithdrawnAtopic DermatitisNetherlands
-
St. Franziskus HospitalCompletedUveitis | Juvenile Idiopathic ArthritisGermany
-
Sirion Therapeutics, Inc.CompletedDry Eye SyndromesUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiomyopathy, Hypertrophic | Heart HypertrophyUnited States
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Acute Renal FailureNorway
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway